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Abstract. Posttranslational modification by covalent
attachment of polyisoprene intermediates to a carboxy-
terminal CAAX-box motif is required for the biologic
function of proteins such as p21-, the supergene
family of ras-related proteins, nuclear lamins, and sub-
units of heterotrimeric G-proteins. Cells grown in the
presence of lovastatin, which inhibits HMG-CoA reduc-
tase and prevents synthesis of intermediates required
for protein prenylation, develop a round, refractile
morphology. Our data indicate that this is due to the
selective loss of actin cables without gross changes in
the microtubular lattice or intermediate filament struc-
ture. Microinjection of a competitive peptide inhibitor
of protein prenyltransferases into the cytoplasm of cells
induces an identical change in morphology with loss
of actin cables. Mevalonate (MVA) reverses the lova-
statin-induced morphologic change by inducing a rapid
repolymerization of actin cables with coincident rever-
SCENT findings have provided insights into new phys-
iologic roles for intermediates in the cholesterol bio-
synthesis pathway (Goldstein and Brown, 1990).
Mevalonate (MVA)' is the precursor of two isoprenoid inter-
mediates, famesyl-pyrophosphate (FPP) and geranylgeranyl-
pyrophosphate (GGPP), that are substrates for posttransla-
tional modifications in which the lipid moiety is covalently
transferred to a diverse group of cellular proteins (Schmidt
et al ., 1984). Farnesylated proteins include the nuclear en-
velope protein laminB (Farnsworth et al., 1989), the gamma
subunit of bovine transducin (Fukada et al., 1990), and ras
proteins (Hancock et al., 1989; Schafer et al., 1989; and
Casey et al., 1989). Data indicate thatmore cellular proteins
are modified by geranylgeranyl than by farnesyl moieties
(Farnsworth et al., 1990; Epstein et al., 1990). These in-
clude the gamma subunits of heterotrimeric G-proteins
(Yamane et al., 1990; Mumby et al., 1990), and members
of the ras-related family of low molecular weight GTP-bind-
1. Abbreviations used in this paper: CHA, cycloheximide; FPP, farnesyl-
pyrophosphate; FT, farnesyl transferase; GGPP, geranylgeranyl-pyrophos-
phate; GGT, geranylgeranyl transferase; MVA, mevalonate.
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sion to the flat morphology. Furthermore, microinjec-
tion of farnesyl-pyrophosphate or geranylgeranyl-pyro-
phosphate into lovastatin-treated cells also results in
rapid morphologic reversion. The morphologic rever-
sion induced by MVA requires the presence of serum,
and is independent of extracellular calcium. The addi-
tion of cycloheximide to the growth medium prevents
lovastatin-induced loss of actin cables, and causes
morphologic reversion of lovastatin-treated cells by a
mechanism that is independent of MVA. AlF4_ induces
morphologic reversion in a manner indistinguishable
from MW These data indicate that prenylated pro-
tein(s) play a critical role in regulating the state of in-
tracellular actin, and that GGPP can rescue the lova-
statin-induced morphologic phenotype in the absence
of upstream intermediates of cholesterol biosynthesis.
We have begun to dissect the signaling events that me-
diate this pathway.
ing proteins, such as G25K (Yamane et al., 1991), the rac
1, rac 2, and ral A proteins (Kinsella et al ., 1991), rap1B(Ka-
wata et al., 1990), rab proteins (Khosravi-Far et al., 1991;
Farnsworth et al., 1991; Kinsella and Maltese, 1991), and
rho A (Yoshida et al., 1991). Carboxy-terminal lipids form
part ofthe hydrophobic signal that targets proteins to various
membranes within the cell where a diverse group of func-
tions are performed (Maltese and Sheridan, 1987). These in-
clude forming part of the nuclear envelope (lamins; Wolda
and Glomset, 1988), playing a crucial role in intracellular
trafficking such as occurs with secretory vesicles (ras-related
proteins; Bourne et al., 1990), and the control ofcell growth
and division (ras proteins; Hancock et al.,, 1989; Schafer et
al ., 1989 ; Casey et al ., 1989) .
Two distinct prenyl-transferases have been identified
which utilize FPP or GGPP as substrates for the covalent
modification of conserved carboxy-terminal CAAX-motifs
(a cysteine residue followed by two aliphatic amino acids and
any amino acid) . The cysteine residue is enzymatically
linked to the lipid via a thioether bond, followed by proteo-
lyticcleavage ofthe three terminal amino acids, and in some
cases carboxyl methylation of the terminal cysteine residue
347(Clarke et el., 1988; Gutierrez et al., 1989). Genetic and
biochemical evidence indicates that famesyltransferase (FT)
and geranylgeranyltransferase (GGT) share a common alpha
subunit but have distinct ß-subunits which account for their
distinct substrate specificities (Chen et al., 1991) . GGT pref-
erentially utilizes leucine or phenylalanine in the X position,
whileFT recognizes a broader spectrum ofamino acids and
often utilizes methionine or serine in the X position (Reiss
et al ., 1991; Yokomama et al., 1991) . Thus, while the spec-
ificity for protein prenylation appears to reside in the CAAX-
box sequence, the functional significance ofthedifferentlipid
modifications remains to be determined.
The discovery that many cellular proteins require prenyla-
tion for biologic function, and that these proteins play key
regulatory roles within the cell, has stimulated experimenta-
tion to identify other cellular processes that are regulated by
prenylation. For more than a decade, it has been knownthat
inhibition of HMG-CoA reductase, the enzyme that cata-
lyzes the rate-limiting stepin cholesterol biosynthesis, leads
to arrest of cell growth and a concomitant change in mor-
phology in which adherent cellsbecome round and refractile
(Schmidt et al., 1982; Goldstein and Brown, 1990). The
metabolic effects of lovastatin are prevented by addition of
MVA (the product of the HMG-CoA reductase reaction) to
the culture medium, but not by exogenous cholesterol, a ma-
jor end product of this metabolic pathway.
In the present study we examine the relationship between
the cholesterol biosynthesis pathway and its effects on cellu-
lar growth and morphology. We have investigated the molec-
ular basis for the lovastatin-induced morphologic change,
and found that actin cables are reversibly depolymerized
when cellsare treated with HMG-CoA reductase inhibitors;
other cytoskeletal structures such as intermediate and thick
filaments do not appear to be affected. This effect is reversed
within minutes by the addition of MVA to the growth
medium or the intracellular injection of MVA, FPP, or
GGPP The data indicate that at leastone prenylated protein
plays a major role in a pathway governing the equilibrium be-
tween filamentous and globular actin.
Materials andMethods
DL-mevalonic acid lactone (MVA) was obtained from Sigma Chemical Co.
(St.Louis, MO) and was used as the lactone form. MVA was stored as a
250 mM solution at -20°C. Lovastatin was kindly provided by A. Alberts
(Merck, Sharp and Dohme Research Laboratories, Rahway, NJ) . Fluores-
cein-phalloidin was obtainedfromMolecular Probes Inc. (Eugene, OR) and
stored as a methanol stock solution at -20°C. DMEM and FCS were pur-
chased from Gibco BRL (Grand Island, NY). Cycloheximide (CHA), ac-
tinomycin D, NaF, AIC13, and EGTA were obtained from Sigma Chemical
Co. (St. Louis, MO.). FPP and GGPP were kindly provided by Dr. Dale
Poulter (University of Utah) . These were stored at -70°C as 50 mM solu-
tions in PBS.
CellCulture
Cells were maintained at 37°C in a humidified incubator with 5% COZ and
grown in DMEM supplemented with 10% FCS and penicillin and strep-
tomycin. The Kl cell line was derived from a human renal cell carcinoma
after collagenase and DNAse treatment ofthe primary tumor. This line has
grown continuously in culture for nearly one year, has a very slow growth
rate, and is contact inhibited upon reaching confluence.
Preparation ofthe OpenAcidForm ofLovastatin
1 g of lovastatin was dissolved in 25 ml of 100% ethanol. 37.5 ml of 0.1 N
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sodium hydroxide was added and the solution was heated for 2 h at 50°C.
The solution was rapidly cooled to room temperature on ice, and the pH
was adjusted to 7.2 with hydrochloric acid. The volume was brought to 250
ml with sterile water, and the resulting 10 mM solution was aliquoted, and
stored at -20°C.
Antibodies
A murine IgGI mAb directed against ß-tubulin was purchased from Sigma
Chemical Co. and used at a dilution of 1:200. A murine IgG2a mAb anti-
body directed against vimentin was obtained from Boehringer Mannheim
Biochemicals (Indianapolis, IN) and diluted 1:5 before use. Cytokeratin was
stained with undiluted murine mAb (tissue reagent) from Becton Dickinson
(Mountain View, CA). Fluorescein-labeled goat anti-mouse IgG (F[aV]Z
specific fragment) was obtained from Organon Teknika Corporation (West
Chester, PA) and used at a dilution of 1:50. The neutralizing mAb Y13-259,
directed against p21" proteins, was purchased from Oncogene Science
(Manhasset, NY).
Fluorescence Microscopy
Cells grown on glass coverslipswerefixed and stained at various times after
culture in lovastatinor the addition ofMVAto the culture medium (morpho-
logic reversion experiments). For staining with fluorescent phalloidin, cells
were washed twice with PBS and fixed in 3.75 % formaldehyde/PBS for 10
min at room temperature. Coverslips were washed twice in PBS, extracted
with acetone at -20°C for 3 min, air dried, and stored at -20°C or stained
immediately. 10 pl ofFITC-phalloidin (equal to one unit) was dried under
vacuum, redissolved in 200141 ofPBS, and 100-20014 were appliedto each
coverslip. Coverslips were incubated in a humidified chamber for 20 min
at room temperature, washed twice in PBS, and mounted with cell side
down in a 1:1 solution of PBS/glycerol, and the edges sealed with nail pol-
ish. Stained cells were stored inthe dark at 4°C. For antibody studies, cells
were fixed in acetone/methanol 1:1 at -20°C for 10 min. Cells were washed
twice in PBS and immediately stained with the primary antibody in a hu-
midified chamber at room temperature. After 30 min, coverslips were
washed twice in PBS and stained with fluorescein-conjugated second anti-
body for 30 min. The cells were washed twice with PBS and mounted as
described above. Cells were viewed with an Olympus microscope through
a 50x or 100x oil immersion lens, and photographed using an Olympus
Exposure Control Unit and Ektar 1000 film.
Quantitation ofCellMorphology
In many experiments, the percent ofmorphologically flat cells as compared
with round, refractile cells was quantitatively determined. This was done
by photomicroscopyofcellcultures (Nikon invertedmicroscope with a 10x
phase contrast lens) at the indicated times after changes in cell culture con-
ditions. Cells contained within two randomly chosen 2 x 3-cm areas of
each photograph were counted (50-100 cells perfield) and expressed as the
percent ofthe total number ofcells which exhibited a flat morphology. The
round, refractile morphology induced bylovastatin was easily distinguished
from cells with a flat morphology, especially with cell lines KI and NIH
3T3 whose normal morphology is extremely flat.
MicroinjectionAssay
For peptide injections, cell lines were seeded onto etched glass coverslips
and cultured in 35-mm dishes with DMEM/10% FCS for -24 h before in-
jection of coded peptide samples (Smith et al., 1990). After injection, cul-
tures were maintained in growth mediumforanadditional 18-24 h at which
time they were scored for morphologic change and stained with FITC-
phylloidin for analysis of actin cables. The peptide TKCVIM corresponds
to the carboxy-terminal six amino acids ofthe human p21K-`WB protein and
contains a CAAX-box sequence (CVIM), while the control TKVCIM does
not (Reiss et al., 1990). These peptides were dissolved in 10 mM DTT, 5 %
DMSO at a final concentration of 2.5 mg/ml. Injected cells received
-10-11 ml. Stock solutions of MVA, FPP, and GGPP were diluted with
PBS to the stated concentrations before injection into lovastatin-treated
cells. FPP and GGPP form micelles in aqueous solutions; this causes clog-
ging of the microinjection needle thus limiting the concentration at which
injections can be made and making estimation of the amount of the com-
pounds injected difficult. Microinjection of ras-specific antibody Y13-259
has been described previously (Smith et al., 1986).
348Results
Molecular Basis of the Lovastatin-induced
Morphologic Change
The molecular basis by which lovastatin and other HMG-
CoA reductase inhibitors induce adherent cells to altertheir
morphology to a round, refractile state has not been eluci-
dated. To investigate the mechanism for this morphologic
change, the effects of lovastatin on the cytoskeletal architec-
ture of cell line Kl were analyzed. KI was derived from a
human renal cell carcinoma, has been continuouslypassaged
under standard cell culture conditions (DMEM/10% FCS),
and grows with an extremely flat morphology such that rele-
vant cytoskeletal structures are well demonstrated by fluo-
rescence microscopy. However, the results described for line
Kl are similar for other cell lines, including NIH 3T3, which
has also been studied extensively.
Kl cells were grown in the presence or absence of lovasta-
tin and cells were fixed and stained with FITC-phalloidin,
which specifically stains filamentous-actin (as in actin ca-
bles), but not actin monomers. As shown in Fig. 1 a, KI cells
grown under normal conditions contain numerous actin ca-
bles which traverse the cell and extend to the plasma mem-
brane. In contrast, Kl cells grown in 30 AM lovastatin for
20 h are round and refractile, and no actin cables are seen
(Fig. 1 b). The diffuse and occasional punctate staining of
rounded cells by FITC-phalloidin suggests that oligomers of
actin persist in these cells although they are not discernible
as discrete structures by light microscopy. To determine
whether this effect of lovastatin on actin cables could be
reversed by MVA, medium was removed from identical cul-
ture plates as shown in Fig. 1 b and replaced with medium
containing 30 AM lovastatin plus 1 mM MVA . Morphologic
reversion to a flat phenotype occurred very rapidly; 15 min
after MVA addition, most cells had regained a flat morphol-
ogy. Accompanying this morphologic reversion was the
reappearance of actin cables, although these were initially
very short and thin, and appeared primarily to be located
peripherally, near the plasma membrane (Fig. 1 c); few ca-
bles traverse the entire cell . After 30 min, numerous actin
cables were apparent which extend the full length of the cell
(Fig. 1 d); these are still thin and wispy as compared to un-
treated cells, suggesting that cross-bundling ofnewly formed
cables by actin-associated proteins is a later event. Within a
few hours, actin cables became indistinguishable from those
in Fig. 1 a (not shown) and the reverted KI cellsproliferated
in media containing MVA and lovastatin until confluence
was attained.
When K1 cells were stained with antibodies specific for
ß-tubulin or vimentin, a differentpattern emerged . As shown
in Fig. 2 a, Kl cells stained with an antibody specific for
tubulin possess an extensive microtubular network. Follow-
ing growth for 20 h in 30 AM lovastatin, the cells undergo
the expected morphologic change; however, the microtubu-
lar array remains intact with no evidence of disassembly
(Fig. 2 b ; viewed at high power). After 15 min of growth in
MVA, the microtubular lattice is again noted to be a poly-
merized network, even in cellsin an early stage of reversion
(Fig. 2, c and d). Similarly, KI cells stained with antibodies
directed against vimentin or cytokeratin demonstrate the
characteristic peri-nuclear meshwork with cytoplasmic ex-
tension, and lovastatin-treated cellsshow no evidence ofdis-
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solution of these intermediate filament complexes (data not
shown) . Thus, the loss ofactin filaments in lovastatin treated
cells does not represent a general effect on all cytoskeletal
components.
Morphologic Change Induced by Inhibition
ofPrenyl-transferases
Todeterminewhetherlovastatin induces morphologic change
via inhibition of protein prenylation, K1, NIH 3T3, and Rat
1 cells were microinjected with synthetic peptides, one of
which is a potent competitive inhibitor of FT, and likely an
inhibitor of GGT as well at the high concentrations micro-
injected. When these cell lines were microinjected with the
inhibitor peptide TKCVIM, 25-35% of the cells in the in-
jected field had become refractile with loss of actin cables
within 20 h (Fig. 3 b, and Table I) . As a control, the peptide
TKVCIM was microinjected. This hexamer is not a substrate
for either prenyltransferase, due to the position of the cys-
teine residue (yet it has the same overall amino acid composi-
tion as the inhibitory peptide). In this case, no morphologic
change distinct from background was noted, andactin cables
were maintained (Fig. 3 a; Table I). From these data we con-
clude that inhibition of prenylation of one or more CAAX-
containing proteins results in a morphologic phenotype in-
distinguishable from that caused by lovastatin and is likely
the result of inhibition of the same metabolic pathway.
Microinjection ofFPPor GGPPInduces
Morphologic Reversion
The previous data suggested that prenylated cellular proteins
were required for maintenance ofactin cables. To further es-
tablish this point, lovastatin-treated cellswere microinjected
with MVA, FPP, or GGPP . As shown in Table II, injection
of each of these compounds leads to morphologic reversion
of the majority of injected cells. No obvious differences in
the kinetics of reversion were noted with the three com-
pounds, as reversion was rapid in all cases. These data indi-
cate that GGPP can induce morphologic reversion in the ab-
sence of other prenyl intermediates such as FPP, suggesting
that proteins that can be modified by geranylgeranyl rather
than farnesyl are responsible for inducing morphologic
reversion . Reversion induced by MVA and FPP may result
from their in vivo conversionto GGPP Other data indepen-
dently support the concept that ras proteins are not required
for morphologic reversion. When lovastatin-treated Kl cells
are coinjected with the ras-specific antibody Y13-259 and
MVA, rapid morphologic reversion ensues (Table II) . Identi-
cal results are observed when Y13-259 is microinjected 1 h
before addition of MVA to the culture medium (data not
shown) . The neutralizing activity of Y13-259 is maintained
in Kl cells, since injection of this antibody into serum-
starved KI cells blocks serum induction of DNA synthesis.
Requirementsfor Serum and Extracellular Calcium
To determine whether the presence of serum in the culture
medium was required for MVA-induced reversion, complete
media was removed from lovastatin-treated cells and re-
placed with DMEM lacking serum but containing 1 mM
MVA and 30 AM lovastatin. As shown in Table III, serum
was required for the initial rapid phase of reversion (note the
lack of reversion at 30 min), but by 60 min the cells were
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350Figure 2 . Lovastatin does not cause gross disruption of the microtubular lattice. (a) Kl cells grown in the absence of lovastatin and stained
with amAbdirected against ß-tubulin . (b) High powerphotograph ofKl cells grown in 30AM lovastatin for 20 h (to attain the refractory
morphology) and stained as ina. (c) Kl cells were grown in lovastatin for20 h at which time 1mM MVAwas added to the culturemedium .
15 min after MVA addition, cells were fixed and stained for ß-tubulin . Note that cells are in different stages of reversion, and that a full
microubular lattice is seen in the partially reverted cells, with no evidence of depolymerization . (d) Higher magnification of refractile
Kl cells from the same culture shown in c . These cells are in an early stage of reversion, and remain quite round and refractile, yet the
microtubular lattice is still apparent . Bars : (a and c) 5 pm; (b and d) 2.5 Fm .
Figure 1. Fluorescent micrographs of FITC-phalloidin-stained Kl cells demonstrating the effect of lovastatin on actin cables . (a) Kl cells
were stained after growth in the absence of lovastatin to demonstrate the normal appearance of actin cables which traverse the cell
and extend up to the plasma membrane . (b) Kl cells were stained 20 h after the addition of 30jM lovastatin to the culturemedium . Cells
are round and refractile (and appear three-dimensional), and while diffuse and occasional punctate staining is seen, no actin filaments
are observed . (c) Cells identical to those in b were grown for 15 min in medium (DMEM/l0% FCS/30 /M lovastatin) to which 1 mM
MVA was added . Note that cells have significantly reverted to a flat phenotype, and that actin filaments are beginning to reform . Many
of these early filaments are very shortand often appear near the cell periphery ; few cables extend across the center of the cell at this stage
of reversion . (d) Kl cells 30 min after the addition ofMVA to culturemedium. Cells are nowcompletely spread on the adherent growth
substrateand actincables are long andnumerous andextend the entire length ofthecells. The panels are ofequal magnification . Bar, 10F,m .
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35 1Figure 3 Inhibition of CAAX-dependent prenyltransferases causes morphologic alteration similar to lovastatin . (a) Kl cells within a pre-
scribed grid were microinjected with peptideKTVCIM (control peptide with noCAAX sequence) and 20h later cells were fixed and stained
with FITC-phalloidin. (b) Kl cells were microinjected with CAAX-containing peptideKTCVIM and stained as ina . Data are quantitated
in Table I . Bar, 10 j,m .
beginning to flatten, and by 2 h after treatment, nearly con-
trol percentages of flat cells were observed .
Intracellular free calcium is an important second mes-
senger for many stimulus-response processes in eukaryotic
cells . To determine whether MVA might act by inducing a
rapid influx of extracellular calcium into the cell, lovastatin-
treated Kl cells were cultured in calcium-free DMEM con-
taining 10% FCS, 30 p,M lovastatin, 1 mM MVA, and 1 or
2mM EGTA . Treatment under these conditions had no effect
on the MVA-induced morphologic reversion (Table III) .
These data suggest that extracellular calcium is not required
Table 1. Microinjection ofa CAAXBox Containing Peptide
Induces Altered Morphology
Preconfluent cells were microinjected with either a CAAX-box containingpep-
tide (TKCVIM) or a control peptide (TKCVIM), and cultured for an additional
20 h in DMEM/10% FCS . Cells within the injected area were then scored for
"% of cells with a refractile morphology ." The standard deviation from four
separate experiments is given in parentheses .
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for MVA-induced morphologic reversion . Also, extracellu-
lar calcium is not required for the kinetically slower rever-
sion induced by cycloheximide (see next section) .
Morphologic Reversion Can BeIndependentofMVA
The rapid repolymerization of actin cables after rescue with
MVA made it unlikely that de novo synthesis of new actin
Table II. Microinjection ofMVA, FPP, or GGPP Induces
Morphologic Reversion ofLovastatin-treated Cells
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K, cells (104) were plated on glass coverslips in 35-mm plates for 24 h . Cul-
tureswere treated withlovastatin (30,uM for 20-24 h) at which time 95% were
round in morphology . Rounded cells were microinjected with samples . Mor-
phological flatting was observed within 15-20 min after injection . Percent flat
cells was calculated 1 h after injection by counting the number of flat cells in
an injected area and dividing by the total number ofinjected cells in that area .
Numbers in parenthesis are SD from four separate injection experiments .
Cell line Peptide
% Cells with refractile
injected : TKCVIM
morphology
TKCVIM
KI 2 34(4 .9)
NIH 3T3 4 37 (3 .2)
Rat 1 1 26(5 .3)
Injected sample Flat cells
PBS 7(2 .8)
GGPP (2 .0 mM) 78(4.5)
FPP (1.25 mM) 69(5 .2)
Mevalonate (5 mM) 92(3.7)
Mevalonate (5 mM) + Y13-259 (4 mg/ml) 81(4 .9)Table III. Serum and Extracellular Calcium Requirements
ofMorphologic Reversion
Kl cells were grown for 20h in 30,uM lovastatin, at which time >90% ofcells
exhibited a refractile morphology. To initiate the experiment, culture medium
was changed to 30 AM lovastatin in DMEM with or without 10% FCS and
the addition of the agents (MVA, CHA, or EGTA) noted. Experiments with
EGTA were performed with calcium-free DMEM . After mediumchange, cells
were photographed at the times indicated and results expressed as "% cells ex-
hibiting a flat morphology."
" MVA was utilized at 1 mM, and CHA at 5 ug/ml.
$ By 2.5 h in culture cell toxicity was induced by Ca medium/EGTA.
4 By 4.0 hours in culture, cell toxicity was observed.
monomers was induced by MVA. To formally exclude this
possibility, experiments were performed in which CHA was
added to cells treated with lovastatin. Lovastatin and CHA
were simultaneously added to preconfluent cultures of K1
cells and morphology assessed after 20 h. As seen in Fig.
4 b, cells treated with lovastatin alone undergo the expected
morphologic change, whereas those treated with lovastatin
plus 5 /,g/ml CHA are protected from the lovastatin effects
and retain a flat morphology (Fig. 4, compare a, b, and c).
Staining of lovastatin/CHA-treated cells with FITC-phal-
loidin revealed abundantactin cables (data not shown). CHA
was effective at doses from 2.5 to 10 ug/ml. Cells cultured
in CHA plus lovastatin retain the flat morphology for -24 h,
then begin to die presumably due to the toxic effects of
prolonged inhibition of protein synthesis. Actinomycin D
treatmentofKI cells (1, 10, or 50lAg/ml) blocked the morpho-
logic changes in a similar manner, although these results
were complicated by cytotoxic effects seen 15 h after actino-
mycin D treatment ofK1 cells. CHA and actinomycin D had
similar effects on lovastatin-treated NIH 3T3 cells.
These data suggested that a labile protein was required for
lovastatin to mediate its effects on cell morphology. If this
were true, CHA might induce reversion of refractile, lova-
statin-treated cells, independently of MVA. To test this hy-
pothesis, KI cells were incubated in 30 wM lovastatin for
20 h, at which time CHA was added to the growth media.
As shown in Fig. 4, the initially highly refractile population
(Fig. 4 b) was induced to revert to a flat morphology over
the ensuing 7 h (Fig. 4, df) . When quantitated the data are
as follows: before the addition ofCHA, 92 % ofKl cellswere
refractile (only 8 % flat). 1 h after CHA addition, 30% of
cells were flat, and after 2.5 and 7 h, 57 and 95 % of cells
had attained a flat morphology, respectively. The kinetics of
CHA-induced reversion are significantly slower than that ob-
served with MVA, and could reflect the halflife of a labile
protein that is required to maintain actin cables in the de-
polymerized state.
AIF4- has been shown to activate trimeric G-proteins by
causing protein-bound GDP to mimic GTP (Bigay et al.,
1987), which can result in the generation of G-protein medi-
ated secondary signals. AIF4 induces a rapid MVA-indepen-
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dent morphologic reversion of lovastatin-treated K1 cells
such that by 30 min after its addition 85 % of Kl cells attain
a flatmorphology(Table IV) . When stained with FITC-phal-
loidin, the reverted cellshadrepolymerizedtheiractincables,
and appeared indistinguishable from those reverted with
MVA (data not shown). Unlike the kinetically slow CHA-
induced reversion, the kinetics of AIF4--induced reversion
are rapid, and closely parallel the effect ofMVA. NaF alone
has a partial effect (as has been observed in other systems),
whichmay be due to the ubiquitous contamination oflabora-
tory waterand glassware with low levels ofaluminum (Stern-
weis and Gilman, 1982; O'Shea et al ., 1987; Donaldson et
al., 1991). However, the specific mechanism of action of
AIF4 in our system is speculative, and could reflect other
pharmacologic activities such as phosphatase inhibition by
the fluoride ion.
Discussion
The molecular basis for the morphologic effects induced by
lovastatin on cultured cells was investigated. Inhibition of
MVA synthesis (by lovastatin) and the concomitant inhibi-
tion of protein prenylation (also demonstrated by injection
of CAAX-box encoding peptides) is accompanied by loss of
actin cables as assessed by light microscopy. The physical
state of actin in these cells is unknown; however, since the
refractile cells are diffusely stained by FITC-phylloidin
(which does not stain actin monomers), it seems likely that
actin exists as short oligomers that retain the capacity to bind
phylloidin. This raises the important issue of the role of
actin-binding proteins in these events, as it seems very likely
that the physiologic activities of such proteins, i.e., severing
and capping of filaments, or binding to actin monomers, will
be important in the processes described here. Interestingly,
during morphologic reversion after MVA addition, the earli-
est discernible actincables are observed at the cell periphery,
near the cell plasma membrane (Fig. 1 c). This is consistent
with electron microscopic data that identified gelsolin bound
to short actin oligomers near cell membranes and suggests
that gelsolin-capped actin oligomers may nucleate actin po-
lymerization at the cell periphery (Hartwig et al., 1989).
While lovastatin treatment has dramatic effects on microfila-
ments, it appears that other constituents of the cell cytoskele-
ton such as the microtubular lattice and intermediate fila-
ments composed of cytokeratin or vimentin are not grossly
affected (although subtle alterations of these structures are
not excluded).
Injection of a peptide inhibitor of famesyl-transferase
leads to a change in morphology and loss of actin cables in-
distinguishable from that observed with lovastatin treatment.
Recently, the substrate preferences of FT and GGT have been
analyzed utilizing synthetic peptides or cloned protein sub-
strates as prenyl-acceptors (Reiss et al., 1991; Yokoyama et
al., 1991). FT prefers serine or methionine in the X-position,
and binding is reduced -10-fold when aliphatic amino acids
occupy this position. GGT utilizes leucine or phenylalanine
preferentially. It appears that half-maximal activities for both
transferases is below 10 uM and that in vitro enzyme
specificity is lost when peptide concentrations approach 50
,.M (Yokoyama et al ., 1991). In our experiments, the intra-
cellular concentration of injected peptides approaches 50
j,M, and thus the distinction cannot be made between inhibi-
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Agent(s)"
%
FCS (10%) EGTA
Cells
15'
exhibiting
30'
a flat morphology
60' 2 .5 h
mm
Lovastatin + - 8 8 8 6
Lovastatin/MVA + - 50 64 83 87
Lovastatin/MVA - - 8 8 43 79
Lovastatin/MVA + 1 50 74 88
Lovastatin/MVA + 2 44 70 88
Lovastatin/CHA + 1 11 11 36 7l§Figure 4 . Cycloheximide prevents the lovastatin-induced morphologic change, andinducesMVAindependent reversion . (a) Control panel
showing the normal morphology of Kl cells grown in DMEM/10% FCS . (b) Kl cells following 20h of growth in 30,uM lovastatin . (c)
Cells treated with 30 t&M lovastatin andCHA(5 /.g/ml) for 20h. Inhibition of protein synthesis prevents the lovastatin-induced morphologic
change . (df) CHA (5 Ag/ml) was added to the culture medium of refractile, lovastatin-treated Kl cells identical to those shown in b .
Cells were cultured for an additional 1 h (d), 2 h (e), or 7 h (f) and photographed under phase-contrast microscopy.
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354Table IV. AlF,- Induces MVA-independent
Morphologic Reversion
Kl cells werecultured for 20h inDMEM/1036 FCS containing 30 AM lovasta-
tin. At that time, MVA (final concentration of 1 mM) or NaF and/or AIC13
(final concentrations of25 mM and 50 AM, respectively) was added to the cul-
ture medium. At the indicated times following these additions, the "% cells ex-
hibiting a flat morphology" was determined.
* At 2 h, AIF4- became toxic to KI cells.
tion ofFT or GGT. However, the lack of effect of the control
peptide indicates that inhibition ofprotein prenylation is the
mechanism of action. The mechanism of lovastatin's effect
upon cellular architecture thus appears to be a depletion of
the prenyl-pyrophosphate substrate(s) required for the pre-
nyltransferase reaction(s).
To further analyze the role ofprenyltransferases in regulat-
ing the actin equilibrium, MVA, FPP, or GGPP was injected
into lovastatin-treated cells; in each case rapid morphologic
reversion ensued. Since the injection ofGGPP does not pro-
vide upstream intermediates such as FPP, it appears that
the GGT reaction is critical in repolymerization of actin.
This suggests further that famesylated proteins (such as ras)
are not required for these events. The latter point is sup-
ported by the failure ofinjected Y13-259 antibody to prevent
MVA-induced morphologic reversion. One caveat is that at
high concentrations ofGGPP, either FT or GGT may become
promiscuous with respect to prenyl-substrate or protein ac-
ceptor and utilize GGPP to modify proteins that would be
famesylated under physiologic conditions. Nevertheless, our
data suggest that one or more geranylgeranyl-modified pro-
tein regulates actin polymerization. Data from others dem-
onstrates that growth of Vero cells in the presence of Clos-
tridium botulinum exoenzyme C3, which ADP-ribosylates
rho and rac family members (but perhaps other cellular pro-
teins as well), results in an altered cell morphology with loss
of actin cables (Chardin et al., 1989). Both rho and rac pro-
teins are known to be modified by carboxy-terminal geranyl-
geranyl (Yoshida et al ., 1991; Kinsella et al., 1991x) . It re-
mains to be determined whether these distinct experimental
approaches are studying manifestations ofthe same biochem-
ical pathway.
When Kl cells were grown in calcium (-) DMEM con-
taining EGTA, the rapid MVA-induced reversion was unaf-
fected. Thus extracellular calcium is not required for actin
repolymerization induced by this pathway ; the possible role
of intracellular stores of calcium in these events is not yet
known. This point is relevant, since some severing and cap-
ping proteins such as gelsolin, are activated by micromolar
concentrations ofcalcium (Yin and Stossel, 1980), resulting
in the net shortening of actin cables.
Surprisingly, lovastatin's morphologic effects are prevented
by coincubation of cellswith CHA. The addition of CHA to
cells previously rendered refractile by lovastatin treatment
leads tomorphologic reversion which is independent ofexog-
Fenton et al. The Mevalonate Pathway Affects Actin Polymerization
enous MVA. The time course ofthis CHA-induced reversion
is much slower than that induced by MVA, with the initial
reversion noted 1-2 h after CHA addition. These data are
consistent with the existence ofa labile cellularprotein which
plays a critical role in regulating the polymerization state of
intracellular actin. The identity and physiologic function of
this protein is not known; it couldplay a regulatory role (i.e.,
as a protein kinase or phosphatase) or directly interact with
actin filaments or monomers.
AIF4-, which is thought to activate heterotrimeric G-pro-
teins and thus induce second messenger formation, also in-
duced MVA-independent reversion. The kinetics were simi-
lar to those of MVA, consistent with a rapid activation of
signaling events required for actin polymerization. Since
AIF4- induces morphologic reversion even in the continued
presence of lovastatin, the AlF4 activation event must be
distal to the prenylated protein(s) in this regulatory pathway.
This hypothesis presumes that AIF4- activates only trimeric
G-proteins, and not other GTP-binding proteins such as
members of the ras supergene family. Recently, it was
demonstrated that AIF4- does not inhibit GDP release from
small GTP binding proteins including ras, rap, rabl, rab3,
and ADP ribosylation factor, suggesting it does not activate
these proteins (Kahn, 1991). The ability of the combination
of NaF and AIC13 to induce morphologic reversion of lova-
statin-treated cells does not prove that the biologic effect
is mediated by trimeric G-proteins. Other mechanisms such
as inhibition of protein phosphatase activity are possible.
Nevertheless, AIF4- does provide a useful pharmacologic
reagent with which to study interactions between the meval-
onate pathway and the cytoskeleton.
The datapresented are consistent with the following model
of lovastatin's effects on actin physiology. Under normal
growth conditions, one or more prenylated proteins are re-
quired to maintain actin in the polymerized state. It pro-
motes polymerization by inhibiting a labile "protein X,"
whose normal activity either directly or indirectly results in
the depolymerization and/or severing ofactin cables. In cells
grown in medium containing lovastatin, the prenylated pro-
tein(s) degrades, and no active species can be synthesized in
the absence of isoprenoid intermediates. This results in the
removal ofthe inhibitory signal on "protein X" with resultant
depolymerization of actin cables and morphologic altera-
tion. In culture medium containing CHA and lovastatin,
"protein X" also degrades and the lovastatin effect cannot be
manifested. Therefore actin cables are "rescued" from the
lovastatin effect by CHA.
The MVA-induced morphologic reversion of lovastatin-
treated cellscan be explained in the following manner. Upon
addition of MVA (or microinjection of FPP or GGPP), the
expanded pool of precursor proteins is activated by prenyla-
tion and other carboxy-terminal processing events. One or
more prenylated protein(s) initiates a signaling cascade that
may include a trimeric G-protein (AIF4 activated), leading
to inactivation of "protein X" and subsequent morphologic
reversion. When CHA is added to lovastatin-treated cells,
"protein X" levels decline, and the blockto actin polymeriza-
tion is removed. Since "protein X" acts distal to the prenylated
regulatory protein, these events are independent of MVA.
The kinetics of this reversion are determined by the degrada-
tion t,rz of "protein X, and hence the kinetics are consid-
erably slower than reversion mediated by MVA, whose time
355
% Cells exhibiting a flat morphology
Agent 15' 30' 60' 2 h
--- (Lovastatin alone) 8 8 8 7
MVA 60 86 90 92
AIF4- 35 85 90 75*
ÀIC13 ND 4 4 ND
NaF ND 21 39 NDcourse is determined by rapid posttranslational and intracel-
lular signaling events. This model is useful in that it makes
a number ofbiochemical predictions that can be tested in the
laboratory.
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